Breast Cancer: Triple - Negative: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797414
  • Drug Pipelines
  • 290 pages
  • Datamonitor Healthcare
1 of 4
The aggressive nature of triple-negative breast cancer and a lack of targeted therapies creates opportunities for pipeline candidates to fulfil areas of high unmet need.

This report addresses the following questions:

- Which branded therapies will have the largest commercial potential in the triple-negative breast cancer market?
- What impact will immunotherapies have on treatment algorithms in triple-negative breast cancer?
- How will competing poly (ADP-ribose)polymerase (PARP) inhibitors Lynparza, niraparib, talazoparib, and veliparib fare against one another?
- How will pipeline therapies aim to address areas of unmet need?
- When will generic and biosimilar therapies enter the market and what impact will they have on revenues?
Note: Product cover images may vary from those shown
2 of 4
FORECAST: TRIPLE-NEGATIVE BREAST CANCER

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Abraxane (albumin-bound paclitaxel)
- Atezolizumab
- Avastin (bevacizumab)
- glembatumumab vedotin
- Halaven (eribulin mesylate)
- Keytruda (pembrolizumab)
- Lynparza (olaparib)
- Niraparib
- sacituzumab govitecan
- Talazoparib
- Veliparib
- Primary Research Methodology

TREATMENT: TRIPLE-NEGATIVE BREAST CANCER

- Executive Summary
- Disease Definition and Diagnosis
- Primary Research Methodology
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Unmet Needs in Triple-Negative Breast Cancer

EPIDEMIOLOGY: TRIPLE-NEGATIVE BREAST CANCER

- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: TRIPLE-NEGATIVE BREAST CANCER

- Executive Summary
- Product Overview
- Product profile: Abraxane
- Product profile: Avastin
- Product profile: Halaven

PIPELINE: TRIPLE-NEGATIVE BREAST CANCER

- Executive Summary
- Clinical Pipeline Overview
- Target Product Profile
- Product profile (late stage): Keytruda
- Product profile (late stage): Lynparza
- Product profile (late stage): atezolizumab
- Product profile (late stage): glembatumumab vedotin
- Product profile (late stage): niraparib
- Product profile (late stage): sacituzumab govitecan
- Product profile (late stage): talazoparib
- Product profile (late stage): veliparib
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll